Fundraising Fox
/Companies
Sign in

OyaGen

Rochester, US · Delaware corporation

Find your way into OyaGen

Each arrow is one introduction. Sign up to fill in the first one.

169 people can intro you to Harold

Ask Craig Dubitsky to introduce you to Harold C. Smith

You →Craig · together at University of Rochester →Harold

Sign up to find every way you can get introduced to OyaGen

  • Your email: who you already know at OyaGen, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the OyaGen team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

OyaGen is a preclinical drug discovery and development company that identifies and optimizes lead compounds as investigational new drugs for infectious diseases and cancer, then licenses or partners them with industry leaders for clinical development. It also offers fee-for-service assay development and high throughput screening to academic and industry partners.

BiotechDeep TechHealthtech

Founders & leadership

HCHarold C. Smith
Harold C. SmithFounderHarold C. Smith is a Professor Emeritus of Biochemistry and Biophysics and Oncology at the University of Rochester School of Medicine and Dentistry who founded OyaGen in 2003 to develop therapeutics for infectious diseases and cancer.
RP
Ryan P. BennettCSO & Laboratory Director
RM
Richard McCloskeyNamed on SEC filing
TF
Thomas FitzgeraldChief Operations Officer
RO
Richard OgdenNamed on SEC filing
RM
Roscoe MooreNamed on SEC filing
KP
Kevin PhelpsChief Financial Officer & Treasurer
JC
Jose CoronasNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$345K disclosed across 1 round · 2017

▶$345KraisedDec 2017 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan BennettExecutive Officer
  • Richard McCloskeyDirector
  • Thomas FitzgeraldExecutive Officer, Promoter
  • Richard OgdenDirector
  • Harold SmithExecutive Officer, Director, Promoter
  • Roscoe MooreDirector
  • Kevin PhelpsExecutive Officer, Director
  • Jose CoronasDirector
Offering amount
$700K
Amount sold
$345K
Minimum investment
$25K
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

ExagenExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
NivagenNivagen provides drug product development services, guiding pharmaceutical companies through the full lifecycle from concept to commercialization, including traditional NDAs, 505(b)(2)s, and complex generics. The company serves pharmaceutical and biotech firms seeking to bring innovative drug products to market with intellectual property protection and accelerated timelines.
IdeagenIdeagen provides compliance and risk management software for regulated industries including aviation, life sciences, and food. The platform helps organizations in high-compliance sectors manage processes, people, and product safety.
LabcyteLabcyte developed acoustic droplet ejection ("Echo") liquid-handling instruments that use focused sound waves to transfer nanoliter-scale liquid volumes between microplates without physical contact. Its technology served drug discovery, genomics, and proteomics workflows in pharma, biotech, and academic labs.

Companies working in the same space as OyaGen.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$299K
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$572.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$600K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does OyaGen do?
OyaGen is a preclinical drug discovery and development company that identifies and optimizes lead compounds as investigational new drugs for infectious diseases and cancer, then licenses or partners them with industry leaders for clinical development. It also offers fee-for-service assay development and high throughput screening to academic and industry partners.
Who founded OyaGen?
OyaGen was founded by Harold C. Smith.
How much funding has OyaGen raised?
OyaGen has disclosed $345K raised across 1 round.
Where is OyaGen headquartered?
OyaGen is headquartered in Rochester, US.